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The blaring theme of the William Tell Overture, with trumpet
fanfare,andits“off-to-the-races”tempoharkensoneofmyfa-
vorite TV shows: The Lone Ranger. In fact, the stirring theme
song was known to me only as “The Lone Ranger,” knowing
nothingaboutGioacchinoRossinioropera.TheLoneRanger,
a masked man played by Clayton Moore, somewhat of a par-
adox and a mystery because only bandits wore masks hiding
their identity. He only used silver bullets, and had a trusted
friend named Tonto (played by Jay Silverheels), an Indian
whoreferredtohimas“Kemosabe.”Whatanunlikelypairing.
AsTheLoneRangergallopedtorearhissteedatthesamedes-
sert rock each week, the announcer would intone something
about: “Recall those thrilling days of yesteryear... ”a n dw e
were enthralled by another episode of a single righteous man
doing deeds that righted wrongs and there was never a hint of
improprietyordirtybackhandedtactics.Corny,huh?Surelyit
would not make it today.
Howard (Skip) Burris brings back some other thrills about
thesubjectofcombinedmodalityuseandthecuriousphenom-
enon of “radiation recall.” Talk about odd pairings, chemo-
therapy was the “chemo-sabe” to the lone ranger of
radiotherapy, but unlike Jay Silverheels and Clayton Moore,
this couple has not always gotten along, retreating to opposite
campsratherthancelebratingtheirsmallstepsofsuccess.Skip
Burris brings to light a new drug, ixabepilone, from a new
class,epothilones,whichstabilizemicrotubules.Itisapproved
foruseinthesecondlineofrefractorybreastcancer.Itpurports
anewinteractionwithradiotherapycharacterizedas“radiation
recall.”Itisacasereportandreviewoftheliterature[1].Skip’s
review relies heavily on the Camidge and Price treatise
from 9 years ago [2], and adds the case reports and other
agents causing “recall” reported in the interim years.
Timing may greatly influence these phenomena. “Recall
versus radiosensitization” is a key concept from the Cam-
idge and Price essay that Burris picks up and adopts. In
“sensitization,” the drugs and chemotherapy are used to-
gether so that the chemotherapy tees up the cells for the
damage by the radiotherapy. The classic use of fluorouracil
and cisplatin fit the bill here. On the other hand, Camidge
and Price distinguished “recall versus impaired healing,”
andcautionthat“allradiationreactionsintheskin[needto]
have completely recovered before a reaction can be said to
produce radiation recall dermatitis” [2]. If radiotherapy has
so injured tissue, bringing chemotherapy in too soon can
exacerbate the toxicity and make a subliminal toxicity
overt. Dr. Burris, in this case report, didn’t seem to accept
this concept. The case report describes such an exacerba-
tionofthedamageproducedbytheradiotherapymorethan
radiationrecall.Butradiationrecallishardtoexplaininthe
first place. Both the Burris and Camidge and Price papers
try to bring reason to what is mysterious and enigmatic. Al-
though they each take pains to describe the dermatologic
phenomena, both admit that there are visceral aspects
(pneumonitis/lung scar, enteritis/bowel obstruction?) that
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sense of why there is a seemingly idiosyncratic reaction on
the first exposure, but nothing when the same drug is
bravely used again after an interval? It is the gap between
either radiotherapy and chemotherapy or chemotherapy
thatmakesthequestionoftiming uncertainandunpredict-
able. So we rely on clinical prudence and anecdotes.
There are more stories about this than episodes of The
Lone Ranger on radio and TV combined.
ThetimingofmodalitieshasbeenaninterestsinceIstarted
my academic career. The analysis by Rafi Catane that influ-
enced the twice-daily radiotherapy with concurrent cisplatin
etoposide small cell regimen [3] had a strong influence. That
report suggested that concurrent therapy produced better sur-
vival, but concurrent therapy for too long increased toxicity
and treatment-related death. Yes, accelerated radiotherapy
fraction schemes are likely to produce more acute toxicity,
with or without drugs known to produce radiation recall, like
doxorubicinorthetaxanes.Thechoiceofagentsalsoisessen-
tial:agentshavingtoxicitytoanorganintheradiotherapyfield
arelikelyabadchoiceforconcurrentorsequentialtherapy,for
example, doxorubicin and the heart. The National Cancer In-
stitute/Radiation Oncology Branch chemotherapy was cyclo-
phosphamide, doxorubicin, and vincristine, and we all know
we can’t do that today, but they did it and had some very pro-
vocative findings despite the toxicity. Today, the answers to
some are to not use either altered fractionation or drugs con-
currently, but there are now two trials testing whether more
willbebetterthanthecondensed3-weekscheduleallusingthe
old, but very friendly to use with radiotherapy, cisplatin and
etoposide. These are all issues of timing and compatibility
ratherthanrecall.Combinedmodalitiesincreasetoxicity,con-
current therapy more than sequential therapy.
Radiotherapy factors have largely been influenced by
moderntreatmentplanningtechniques.Thisisnottheplaceto
gointoanydetailaboutthecomplexitiesofradiotherapytreat-
ment planning, but the condensed version is that many beams
directedatadefinedtargetreducethedosetosurroundingnor-
maltissuesascomparedwithone,two,orfewbeams,andalso
reduce the dose per fraction. As the volumes of the targets in-
crease, more normal tissues get radiotherapy, and acute and
delayed effects increase proportionately.
In Dr. Burris’ case report, the radiotherapy model was to
treat 10 of 12 thoracic vertebrae (a large field) with a pro-
tracted treatment regimen that caused excessive toxicity, both
to the skin and to the esophagus. It was not healed/repaired
whentheixabepilonewasdelivered.Thisunmaskedtheradio-
therapytoxicity—likeTontopullingTheLoneRanger’smask
off, treachery not cooperation. Perhaps the patient selection,
performancestatus,negativenitrogenbalance,andotherphys-
ical factors may have contributed. However, suggesting that
ixabepiloneistheculpritisfalse...t h edelayedskinrecovery
might be worse, but this really isn’t recall. There is ample ev-
idenceforsinglefractiontherapyproducingreliefandnomore
thanequaltoxicity[4,5].Inmanyquarters,thelongerfractions
are justified under the mistaken notion that they are “less
toxic.” Sadly, in some places, the profit motive plays a role in
whether, consciously or unconsciously, to use many rather
than few fractions. The Lone Ranger knows that a single frac-
tion of 8 Gy is a silver bullet at least eight times out of 10, and
in failures an additional single fraction rescues most.
Chemotherapyandradiotherapycanworktogetherlikethe
Lone Ranger and Tonto...w eneed to be “chemo savvy” as
well as “radio savvy” rather than “tonto” (Spanish for stupid).
We should not confuse sensitizing or inhibition or delayed re-
pairwiththesomewhatmysteriousandidiosyncraticradiation
recall. New ways of delivering radiotherapy make identifica-
tion of the radiotherapy ports much less obvious. The dose on
entry of each beam is remarkably lower, and inversely related
to the number of beams. It is unusual to see skin reactions in
multipleportbeamarrangements.Wemayspendmoretimein
target identification (treatment planning) and beam arrange-
ments, giving dosimetrists more work. Moreover, one of the
perverserealitiesisthatradiotherapydepartmentsmaybepaid
less to do it the right way, then making believe it is safer and
stretching the treatment out for more reimbursement.
Although it makes sense that ixabepilone may delay
healing from radiotherapy toxicity, it causes alopecia in
abouthalfofthepatientstreated,andcutaneousreactionsin
5%;thedescribedreactionisnotradiationrecallbasedon
the facts of this case. The fault seems to lie more with the
radiotherapy techniques and starting treatment before the
radiotherapy reactions subsided. The timing of the modali-
tieswasmaladroit,morethantheenigmaticradiationrecall.
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